|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
US8236557B2
(en)
*
|
2008-05-28 |
2012-08-07 |
University Of Missouri-Columbia |
Hybrid-AAV vectors to deliver large gene expression cassette
|
|
ES2634118T3
(es)
|
2009-02-11 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Vectores de virus modificados y métodos para fabricar y utilizar los mismos
|
|
ES2683695T3
(es)
|
2010-01-12 |
2018-09-27 |
The University Of North Carolina At Chapel Hill |
Repeticiones terminales invertidas restrictivas para vectores virales
|
|
CA2788682C
(en)
|
2010-02-05 |
2019-03-05 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for enhanced parvovirus transduction
|
|
EP4234571A3
(en)
|
2011-02-10 |
2023-09-27 |
The University of North Carolina at Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
WO2013075008A1
(en)
|
2011-11-16 |
2013-05-23 |
University Of Florida Research Foundation Inc. |
Aav dual vector systems for gene therapy
|
|
CN103405774A
(zh)
*
|
2012-10-24 |
2013-11-27 |
尹海芳 |
一种新型药物靶向运输辅助剂
|
|
WO2014081855A1
(en)
*
|
2012-11-20 |
2014-05-30 |
Universite De Montreal |
Methods and compositions for muscular dystrophies
|
|
US9624282B2
(en)
*
|
2012-11-26 |
2017-04-18 |
The Curators Of The University Of Missouri |
Microdystrophin peptides and methods for treating muscular dystrophy using the same
|
|
CA2904396A1
(en)
|
2013-03-15 |
2014-09-18 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav vectors
|
|
EP3517612A1
(en)
|
2013-03-15 |
2019-07-31 |
The University of North Carolina At Chapel Hill |
Synthetic adeno-associated virus inverted terminal repeats
|
|
WO2016115382A1
(en)
|
2015-01-14 |
2016-07-21 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
AU2016206518B2
(en)
|
2015-01-16 |
2020-03-05 |
University Of Washington |
Novel micro-dystrophins and related methods of use
|
|
CA2977071A1
(en)
|
2015-02-20 |
2016-08-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for attenuated chlamydia as vaccine and vector
|
|
GB201507842D0
(en)
*
|
2015-05-07 |
2015-06-17 |
New Royal Holloway & Bedford |
Production of large-sized microdystrophins in an AAV-based vector configuration
|
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
MA45819A
(fr)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
|
KR102877920B1
(ko)
|
2015-11-16 |
2025-10-30 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
|
|
JP7406783B2
(ja)
|
2015-12-14 |
2023-12-28 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
|
|
HUE066442T2
(hu)
|
2016-04-15 |
2024-08-28 |
Res Institute At Nationwide |
ß-szarkoglikán és mikroRNS-29 adenoasszociáltvírus-vektorral történõ bejuttatása és izomdisztrófia kezelése
|
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
EP4011206B1
(en)
*
|
2016-06-21 |
2023-11-01 |
The Curators of the University of Missouri |
Modified dystrophin proteins
|
|
IL263801B2
(en)
|
2016-07-26 |
2024-01-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
KR102759317B1
(ko)
|
2016-08-19 |
2025-01-31 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
|
|
MX2019006614A
(es)
|
2016-12-07 |
2019-10-15 |
Univ Florida |
Adnc del antagonista del receptor de interleucina-1.
|
|
EP3592848A1
(en)
|
2017-03-10 |
2020-01-15 |
Genethon |
Treatment of glycogen storage disease iii
|
|
EP4303225B1
(en)
|
2017-03-15 |
2025-11-26 |
The University of North Carolina at Chapel Hill |
Polyploid adeno-associated virus vectors and methods of making and using the same
|
|
JP7162021B2
(ja)
|
2017-03-17 |
2022-10-27 |
ニューカッスル ユニバーシティ |
筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
|
|
CN110892062A
(zh)
|
2017-05-05 |
2020-03-17 |
佛罗里达大学研究基金会 |
表达耳畸蛋白的组合物和方法
|
|
US11534501B2
(en)
|
2017-10-18 |
2022-12-27 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
SG11202006722RA
(en)
|
2018-01-31 |
2020-08-28 |
Res Inst Nationwide Childrens Hospital |
Gene therapy for limb-girdle muscular dystrophy type 2c
|
|
CN112041442A
(zh)
|
2018-02-28 |
2020-12-04 |
北卡罗来纳大学查佩尔希尔分校 |
用于逃避抗体的病毒载体的方法和组合物
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
EP3773743A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
WO2019195449A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
EP3780952A4
(en)
|
2018-04-16 |
2022-03-09 |
The Trustees of the University of Pennsylvania |
COMPOSITIONS AND METHODS OF TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
|
JP7331011B2
(ja)
|
2018-04-27 |
2023-08-22 |
デシベル セラピューティクス インコーポレイテッド |
ミオシン１５プロモーター及びその使用
|
|
US11660353B2
(en)
|
2018-04-27 |
2023-05-30 |
Decibel Therapeutics, Inc. |
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
|
|
WO2019217513A2
(en)
|
2018-05-09 |
2019-11-14 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
MY208145A
(en)
|
2018-06-18 |
2025-04-18 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
WO2019246544A2
(en)
|
2018-06-22 |
2019-12-26 |
Asklepios Biopharmaceutical, Inc. |
Vectors for gene delivery that persist within cells
|
|
KR20210028162A
(ko)
|
2018-06-29 |
2021-03-11 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
지대근 이영양증 2a형을 치료하기 위한 재조합 아데노 연관 바이러스 생성물 및 방법
|
|
WO2020093018A1
(en)
|
2018-11-01 |
2020-05-07 |
University Of Florida Research Foundation, Incorporated |
A codon optimized otoferlin aav dual vector gene therapy
|
|
CA3129422A1
(en)
|
2019-02-08 |
2020-08-13 |
Decibel Therapeutics, Inc. |
Myosin 15 promoters and uses thereof
|
|
WO2020163743A1
(en)
|
2019-02-08 |
2020-08-13 |
Decibel Therapeutics, Inc. |
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
|
|
CA3131390A1
(en)
|
2019-02-26 |
2020-09-03 |
Research Institute Of Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
CA3130196A1
(en)
*
|
2019-03-25 |
2020-10-01 |
Isabelle Richard |
Production of large-sized quasidystrophins using overlapping aav vectors
|
|
WO2020219656A1
(en)
|
2019-04-26 |
2020-10-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
CN114207120A
(zh)
|
2019-05-30 |
2022-03-18 |
坚固生物科技公司 |
重组疱疹病毒载体
|
|
AU2020311399A1
(en)
*
|
2019-07-10 |
2022-02-17 |
University Of Washington |
Non-viral immuno-targeting
|
|
HRP20240505T1
(hr)
|
2019-08-21 |
2024-07-05 |
Research Institute At Nationwide Children's Hospital |
Dostava alfa-sarkoglikana vektorom povezanim s adenovirusom i liječenje mišićne distrofije
|
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
AU2020378619A1
(en)
|
2019-11-06 |
2022-06-09 |
Association Institut De Myologie |
Combined therapy for muscular diseases
|
|
KR20220107222A
(ko)
*
|
2019-11-28 |
2022-08-02 |
리젠엑스바이오 인크. |
마이크로디스트로핀 유전자 치료 작제물 및 이의 용도
|
|
CN115666658A
(zh)
|
2020-04-01 |
2023-01-31 |
佛罗里达州大学研究基金会 |
具有提高的治疗ush1b的安全性的双aav-myo7a载体
|
|
MX2022013477A
(es)
*
|
2020-04-29 |
2022-11-30 |
Bristol Myers Squibb Co |
Distrofinas miniaturizadas con dominios de fusion de espectrina y usos de las mismas.
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
WO2022093769A1
(en)
|
2020-10-28 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
JP2023547992A
(ja)
|
2020-10-28 |
2023-11-15 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
二重グリカン結合ａａｖ２．５ベクターのための方法および組成物
|
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向ｔ細胞之ａａｖ載體
|
|
WO2022216749A1
(en)
|
2021-04-05 |
2022-10-13 |
Solid Biosciences Inc. |
Recombinant herpesvirales vector
|
|
WO2022221529A1
(en)
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
|
CA3216744A1
(en)
*
|
2021-04-26 |
2022-11-03 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
US20240390522A1
(en)
*
|
2021-09-28 |
2024-11-28 |
University Of Florida Research Foundation, Incorporated |
Gene therapy for duchenne muscular dystrophy
|
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
CN115960946A
(zh)
*
|
2021-10-09 |
2023-04-14 |
中国科学院分子植物科学卓越创新中心 |
调节植物镁离子吸收和转运的方法
|
|
EP4219726A1
(en)
|
2021-10-15 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
CA3248878A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Dinaqor Ag |
GENE THERAPY COMPOSITION AND TREATMENT OF DYSTROPHIN-RELATED CARDIOMYOPATHY
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
WO2023150687A1
(en)
|
2022-02-04 |
2023-08-10 |
Ginkgo Bioworks, Inc. |
Recombinant adeno-associated virus vectors, and methods of use thereof
|
|
US20250288641A1
(en)
*
|
2022-04-27 |
2025-09-18 |
The Curators Of The University Of Missouri |
Micro-dystrophin for heart protection
|
|
WO2024124019A2
(en)
|
2022-12-07 |
2024-06-13 |
Ginkgo Bioworks, Inc. |
Aav vectors targeting hematopoietic stem cells
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2025017168A1
(en)
*
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|